TX-SOFTSERVE
SoftServe , a leading digital authority and consulting company, has opened delivery offices in Guadalajara, Mexico and Medellín, Colombia as part of its strategy to extend global delivery capabilities to Latin America. SoftServe now has 30 delivery center locations globally, Guadalajara and Medellín are the first in Latin America. The company’s plans to expand also include opening another delivery office in Chile.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005015/en/
“As our client roster continues to grow, both new and existing customers are requesting more digital engineering to support their transformations,” said Chris Baker, Chief Executive Officer at SoftServe. “Delivery offices in Latin America will better connect our clients to top talent in the region and will more efficiently support operations within these time zones. SoftServe maintains a long-term strategy to expand a truly global footprint of delivery centers, and we are thrilled about this next step into Latin America.”
With over 500,000 IT professionals in software engineering and 350,000 IT graduates, annually, throughout Mexico, Colombia, and Chile, and given the geographical proximity to the United States, Latin America is an attractive destination for the global delivery operations of major technology players. Opening this vibrant new talent region will support SoftServe’s growth and will help accelerate the execution of its global delivery expansion.
“We are planning to welcome more than 3,000 local people in this region to our global team by 2025,” said Keith Rozmus, North America Division President at SoftServe. “Our presence in Latin America will allow us to bring value to our North American clients by offering 24/7 nearshoring and offshoring options with minimum time shifts. We will also create new opportunities investing in local communities and building learning and re-skilling capabilities for local talent.”
SoftServe aims to bring its best practices and benefits to employees in Latin America. The company will offer associates highly competitive learning solutions powered by SoftServe University , professional certifications, and international assignments. People Excellence , SoftServe’s proprietary professional development platform, will help accelerate career development by tracking achievements and providing a roadmap for gaining new expertise. Meaningful project assignments and a great work environment are highly influential factors for productivity and happiness, and with the current 84 Employee Net Promoter Score, SoftServe will aim to become an employer of choice in Latin America. The company will also give back to local communities by empowering its people to engage in social responsibility activities, including Open Eyes charities and Open/Tech pro bono technology initiatives.
To learn more about SoftServe’s presence in Latin America, please visit the company’s website .
About SoftServe
Employing more than 13,000 associates in 41 centers, offices, and client locations globally, SoftServe has a proven track record in healthcare and life sciences, financial services and insurance, retail, high-tech (ISVs), manufacturing and energy industries. The company offers deep expertise across software engineering, cloud and DevOps, big data and analytics, AI and machine learning, the Internet of Things, experience design and platforms, extended reality (XR) and robotics.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005015/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom